News & Videos - GRIFOLS - English

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Grifols is the subject of a report issued by Gotham City Research on...

LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Grifols is the subject of a report issued by Gotham City Research on...

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Grifols is the subject of a report issued by Gotham City Research on...

LOS ANGELES, CA / ACCESSWIRE / May 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Grifols is the subject of a report issued by Gotham City Research on...

LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Grifols is the subject of a report issued by Gotham City Research on...

Grifols 2023 Annual Report on Form 20-F filed with the SEC PR Newswire BARCELONA, Spain, April 19, 2024 BARCELONA, Spain , April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023 , with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report on...

The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the world An engineering masterwork, the Clayton site is a model for new Grifols...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS PR Newswire NEW YORK, March 27, 2024 NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Grifols and certain of its officers and/or directors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS PR Newswire NEW YORK, March 19, 2024 NEW YORK , March 19, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Grifols and certain of its officers and/or directors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS PR Newswire NEW YORK, March 11, 2024 NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Grifols and certain of its officers and/or directors...

In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard of care, while maintaining an excellent safety profile Regulatory approval process in Europe and United States set to begin in Q4 2024. It would be the first FC approved for an AFD indication in the U.S. in a global market for AFD with an estimated potential of USD 800 million This milestone is...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS PR Newswire NEW YORK, Feb. 7, 2024 NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Grifols and certain of its officers and/or directors have...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS PR Newswire NEW YORK, Jan. 30, 2024 NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Grifols and certain of its officers and/or directors...

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF PR Newswire NEW YORK, Jan. 26, 2024 NEW YORK , Jan. 26, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Grifols, S.A. (NASDAQ: GRFS) (OTC: GIKLY, GIFOF, GIFLF) resulting from allegations that Grifols may have issued...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS PR Newswire NEW YORK, Jan. 22, 2024 NEW YORK , Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Grifols and certain of its officers and/or directors...

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF PR Newswire NEW YORK, Jan. 18, 2024 NEW YORK , Jan. 18, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Grifols, S.A. (NASDAQ: GRFS) (OTC: GIKLY, GIFOF, GIFLF) resulting from allegations that Grifols may have issued materially misleading...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS PR Newswire NEW YORK, Jan. 14, 2024 NEW YORK , Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Grifols and certain of its officers and/or directors...

GRFS SHAREHOLDER ALERT: Johnson Fistel Investigates Grifols, S.A. Following Short Seller Report PR Newswire SAN DIEGO, Jan. 11, 2024 SAN DIEGO , Jan. 11, 2024 /PRNewswire/ -- Johnson Fistel, LLP is investigating Grifols, S.A. (NASDAQ: GRFS ), for potential securities law violations. Shareholders who have incurred losses on their investment in the company are encouraged to contact the firm to learn about potentially recovering their losses. For more details on the investigation, visit...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF PR Newswire NEW YORK, Jan. 10, 2024 NEW YORK , Jan. 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Grifols, S.A. (NASDAQ: GRFS) (OTC: GIKLY, GIFOF, GIFLF) resulting from allegations that Grifols may have issued materially...

Thinking about buying stock in Grifols, Esperion Therapeutics, Rithm Capital, Applied Optoelectronics, or Seres Therapeutics? PR Newswire NEW YORK, Jan. 9, 2024 NEW YORK , Jan. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRFS, ESPR, RITM, AAOI, and MCRB. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. GRFS:...